🇺🇸 FDA
Patent

US 10434167

Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin

granted A61KA61K2039/55555A61K2039/55572

Quick answer

US patent 10434167 (Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin) held by The Government of the United States, as represented by the Secretary of the Army expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Government of the United States, as represented by the Secretary of the Army
Grant date
Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/55555, A61K2039/55572, A61K2039/55577, A61K39/12